Deep learning approach for automated hMPV classification.

Human metapneumovirus (hMPV) is a significant cause of respiratory illness, particularly in children, elderly individuals, and immunocompromised patients. Despite its clinical relevance, hMPV poses diagnostic challenges due to its symptom similarity with other respiratory illnesses, such as influenza and respiratory syncytial virus (RSV), and the lack of specialized detection systems. Traditional diagnostic methods are often inadequate for providing rapid and accurate results, particularly in low-resource settings. This study proposes a novel deep learning framework, referred to as hMPV-Net, which leverages Convolutional Neural Networks (CNNs) to facilitate the precise detection and classification of hMPV infections. The CNN model is designed to perform binary classification by differentiating between hMPV-positive and hMPV-negative cases. To address the lack of real-world patient data, simulated image datasets were used for model training and evaluation, allowing the model to generalize to various clinical scenarios. A key challenge in developing this model is the imbalance within the dataset, where hMPV-positive cases are often underrepresented. To mitigate this, the framework incorporates advanced techniques such as data augmentation, weighted loss functions, and dropout regularization, which help to balance the dataset, improve model robustness, and enhance classification accuracy. These techniques are crucial in addressing issues such as overfitting and generalization, which are common when working with limited datasets in medical imaging tasks. The dataset used for model training and testing consists of 10,000 samples, with an equal distribution of hMPV-positive and hMPV-negative cases. Experimental results demonstrate that the hMPV-Net model achieves a high test accuracy of 91.8%, along with impressive test precision, recall, and F1-score values around 92%. These metrics indicate that the model performs exceptionally well in classifying both hMPV-positive and hMPV-negative cases. Furthermore, the model exhibits superior computational efficiency, requiring only 3.2 GFLOPs, which is significantly lower than other state-of-the-art models such as ResNet-50 and VGG-16. This reduction in computational cost makes the model suitable for deployment in resource-constrained healthcare environments, where computing power and infrastructure may be limited.